The Promoting Resilience in Stress Management (PRISM) intervention for adolescents and young adults receiving hematopoietic cell transplantation: a randomized controlled trial protocol

Kaitlyn M Fladeboe, Samantha Scott, Liam Comiskey, Chuan Zhou, Joyce P Yi-Frazier, Abby R Rosenberg, Kaitlyn M Fladeboe, Samantha Scott, Liam Comiskey, Chuan Zhou, Joyce P Yi-Frazier, Abby R Rosenberg

Abstract

Background: Psychological distress is prevalent among adolescents and young adults (AYAs) receiving hematopoietic cell transplantation (HCT). The Promoting Resilience in Stress Management (PRISM) intervention is a resilience-coaching program that has been shown to mitigate distress and improve quality of life among AYAs receiving chemotherapy for newly diagnosed or advanced cancer. This article describes the protocol of an ongoing randomized-controlled trial (RCT) examining the efficacy of PRISM among AYAs receiving HCT for cancer and/or blood disorders.

Methods/design: The goal of this multi-site, parallel, RCT is to evaluate the effect of PRISM compared to psychosocial usual care (UC) among AYAs receiving HCT. Our primary hypothesis is that AYAs who receive PRISM will report lower depression and anxiety 6-months following enrollment compared to those who receive UC. The PRISM program includes four scripted coaching sessions targeting skills in stress-management, goal setting, cognitive-restructuring, and meaning-making, followed by a facilitated family meeting. Sessions are delivered one on one, 1-2 weeks apart, in-person or via videoconference. We aim to recruit 90 AYAs from 4 US pediatric AYA oncology centers. Eligible AYAs are aged 12-24 years; receiving HCT for malignancy or a bone marrow failure syndrome associated with cancer predisposition; < 4 weeks from their HCT date; able to speak English and read in English or Spanish; and cognitively able to complete sessions. Enrolled AYAs are randomized 1:1 within each site to receive PRISM+UC or UC alone. AYAs on both study-arms complete patient-reported outcome surveys at baseline, 3- and 6-months. Age-valid instruments assess depression and anxiety, overall and cancer-specific health-related quality of life, symptom burden, resilience, and hope. Covariate-adjusted regression models will compare AYA-reported depression and anxiety at 6-months in the PRISM versus UC groups. Secondary and exploratory objectives include assessments of PRISM's cost-effectiveness and its impact on (i) parent and caregiver quality of life and mental health, (ii) pharmaco-adherence to oral graft-versus-host disease (GVHD) prophylaxis, (iii) biologic outcomes such as transplant engraftment and graft-versus-host disease, and (iv) biomarkers of stress such as heart rate variability and the Conserved Transcriptional Response to Adversity (CTRA) gene expression profile.

Discussion: If successful, this study has the potential to address a critical gap in whole-patient care for AYAs receiving HCT.

Trial registration: ClinicalTrials.gov Identifier NCT03640325 , August 21, 2018.

Keywords: AYA; Cancer; Childhood; Hematopoietic cell transplant; Mental health; Palliative care; Pediatrics; Psychosocial outcomes; Quality of life; Resilience.

Conflict of interest statement

The authors declare they have no competing interests.

© 2022. The Author(s).

References

    1. Armenian SH, Sun CL, Kawashima T, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the bone marrow transplant survivor study (BMTSS) and childhood Cancer survivor study (CCSS) Blood. 2011;118(5):1413–1420. doi: 10.1182/blood-2011-01-331835.
    1. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the childhood Cancer survivor study. Ann Fam Med. 2004;2(1):61–70. doi: 10.1370/afm.26.
    1. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin. 2004;54(4):208–236. doi: 10.3322/canjclin.54.4.208.
    1. Martin PJ, Counts GW, Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011–1016. doi: 10.1200/JCO.2009.25.6693.
    1. Chow EJ, Mueller BA, Baker KS, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med. 2011;155(1):21–32. doi: 10.7326/0003-4819-155-1-201107050-00004.
    1. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109(4):1765–1772. doi: 10.1182/blood-2006-05-022335.
    1. Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(1):71–77. doi: 10.1200/JCO.2011.38.4594.
    1. Bishop MM, Beaumont JL, Hahn EA, et al. Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls. J Clin Oncol. 2007;25(11):1403–1411. doi: 10.1200/JCO.2006.07.5705.
    1. Meyers CA, Weitzner M, Byrne K, Valentine A, Champlin RE, Przepiorka D. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol. 1994;12(4):820–826. doi: 10.1200/JCO.1994.12.4.820.
    1. Packman W, Weber S, Wallace J, Bugescu N. Psychological effects of hematopoietic SCT on pediatric patients, siblings and parents: a review. Bone Marrow Transplant. 2010;45(7):1134–1146. doi: 10.1038/bmt.2010.74.
    1. Pot-Mees CC, Zeitlin H. Psychosocial consequences of bone marrow transplantation in children: a preliminary communication. J Psychosoc Oncol. 1987;5(2):73–81.
    1. Steele AC, Mullins LL, Mullins AJ, Muriel AC. Psychosocial interventions and therapeutic support as a standard of Care in Pediatric Oncology. Pediatr Blood Cancer. 2015;62(Suppl 5):S585–S618. doi: 10.1002/pbc.25701.
    1. Kazak AE, Abrams AN, Banks J, et al. Psychosocial assessment as a standard of Care in Pediatric Cancer. Pediatr Blood Cancer. 2015;62(Suppl 5):S426–S459. doi: 10.1002/pbc.25730.
    1. Patenaude AF, Pelletier W, Bingen K. Communication, documentation, and training standards in pediatric psychosocial oncology. Pediatr Blood Cancer. 2015;62(Suppl 5):S870–S895. doi: 10.1002/pbc.25725.
    1. National_Comprehensive_Cancer_Network_(NCCN) NCCN Guidelines: Adolescent and young adult (AYA) Oncology. 2016.
    1. American Academy of Pediatrics Committee on bioethics and committee on hospital care. Palliative care for children. Pediatrics. 2000;106(2 Pt 1):351–357.
    1. Meghani SH, Hinds PS. Policy brief: The Institute of Medicine report Dying in America: Improving quality and honoring individual preferences near the end of life. Nurs Outlook. 2015;63(1):51–9.
    1. Rosenberg AR, Yi-Frazier JP, Eaton L, et al. Promoting resilience in stress management: a pilot study of a novel resilience-promoting intervention for adolescents and young adults with serious illness. J Pediatr Psychol. 2015;40(9):992–999. doi: 10.1093/jpepsy/jsv004.
    1. Carver CS. Enhancing adaptation during treatment and the role of individual differences. Cancer. 2005;104(S11):2602–2607. doi: 10.1002/cncr.21247.
    1. Van Der Lee ML, Garssen B. Mindfulness-based cognitive therapy reduces chronic cancer-related fatigue: a treatment study. Psycho-Oncology. 2012;21(3):264–272. doi: 10.1002/pon.1890.
    1. Gillham JE, Reivich KJ, Freres DR, et al. School-based prevention of depressive symptoms: a randomized controlled study of the effectiveness and specificity of the Penn resiliency program. J Consult Clin Psychol. 2007;75(1):9. doi: 10.1037/0022-006X.75.1.9.
    1. Lau N, Bradford MC, Steineck A, et al. Exploratory analysis of treatment response trajectories in the PRISM trial: models of psychosocial care. Psycho-Oncology. 2019;28(7):1470–1476. doi: 10.1002/pon.5098.
    1. Rosenberg AR, Bradford MC, McCauley E, et al. Promoting resilience in adolescents and young adults with cancer: results from the PRISM randomized controlled trial. Cancer. 2018;124(19):3909–3917. doi: 10.1002/cncr.31666.
    1. Steineck A, Bradford MC, Lau N, Scott S, Yi-Frazier JP, Rosenberg AR. A psychosocial Intervention’s impact on quality of life in AYAs with Cancer: a post hoc analysis from the promoting resilience in stress management (PRISM) randomized controlled trial. Children. 2019;6(11):124. doi: 10.3390/children6110124.
    1. Nansel TR, Iannotti RJ, Liu A. Clinic-integrated behavioral intervention for families of youth with type 1 diabetes: randomized clinical trial. Pediatrics. 2012;124:e866–e873. doi: 10.1542/peds.2011-2858.
    1. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002;52(2):69–77. doi: 10.1016/S0022-3999(01)00296-3.
    1. Verhoof EJ, Maurice-Stam H, Heymans HS, Evers AW, Grootenhuis MA. Psychosocial well-being in young adults with chronic illness since childhood: the role of illness cognitions. Child Adolesc Psychiatry Ment Health. 2014;8(1):12. doi: 10.1186/1753-2000-8-12.
    1. van der Geest IM, van Dorp W, Hop WC, et al. Emotional distress in 652 Dutch very long-term survivors of childhood cancer, using the hospital anxiety and depression scale (HADS) J Pediatr Hematol Oncol. 2013;35(7):525–529. doi: 10.1097/MPH.0b013e31829f2799.
    1. Wolfe J, Orellana L, Cook EF, et al. Improving the care of children with advanced cancer by using an electronic patient-reported feedback intervention: results from the PediQUEST randomized controlled trial. J Clin Oncol. 2014;32(11):1119–1126. doi: 10.1200/JCO.2013.51.5981.
    1. Wolfe J, Orellana L, Ullrich C, et al. Symptoms and distress in children with advanced Cancer: prospective patient-reported outcomes from the PediQUEST study. J Clin Oncol. 2015;33(17):1928–1935. doi: 10.1200/JCO.2014.59.1222.
    1. Collins JJ, Byrnes ME, Dunkel IJ, et al. The measurement of symptoms in children with cancer. J Pain Symptom Manag. 2000;19(5):363–377. doi: 10.1016/S0885-3924(00)00127-5.
    1. Collins JJ, Devine TD, Dick GS, et al. The measurement of symptoms in young children with cancer: the validation of the memorial symptom assessment scale in children aged 7-12. J Pain Symptom Manag. 2002;23(1):10–16. doi: 10.1016/S0885-3924(01)00375-X.
    1. Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL™ in pediatric cancer: reliability and validity of the pediatric quality of life inventory™ generic core scales, multidimensional fatigue scale, and cancer module. Cancer. 2002;94(7):2090–2106. doi: 10.1002/cncr.10428.
    1. Snyder CR, Harris C, Anderson JR, et al. The will and the ways: development and validation of an individual-differences measure of hope. J Pers Soc Psychol. 1991;60(4):570–585. doi: 10.1037/0022-3514.60.4.570.
    1. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson resilience scale (CD-RISC) Depress Anxiety. 2003;18(2):76–82. doi: 10.1002/da.10113.
    1. Campbell-Sills L, Cohan SL, Stein MB. Relationship of resilience to personality, coping, and psychiatric symptoms in young adults. Behav Res Ther. 2006;44(4):585–599. doi: 10.1016/j.brat.2005.05.001.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57(1):289–300.
    1. Diehr P, Johnson LL. Accounting for missing data in end-of-life research. J Palliat Med. 2005;8(Suppl 1):S50–S57. doi: 10.1089/jpm.2005.8.s-50.
    1. Kurland BF, Heagerty PJ. Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths. Biostatistics. 2005;6(2):241–258. doi: 10.1093/biostatistics/kxi006.
    1. Little RRD. Statistical analysis with missing data. New York: Wiley; 1987.
    1. Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: a practical guide. Stat Med. 2020;39(21):2815–2842. doi: 10.1002/sim.8569.
    1. Kenward MG. Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation. Clinical Investigation. 2015;5(3):311–320. doi: 10.4155/cli.14.132.
    1. Rosenberg AR, Bradford MC, Barton KS, et al. Hope and benefit finding: results from the PRISM randomized controlled trial. Pediatr Blood Cancer. 2019;66(1):e27485. doi: 10.1002/pbc.27485.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir